https://www.arubahealthmonitor.com/article/904364603-vtv-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Aruba Health Monitor en PressRelease 2026-04-07T20:15:00+00:00 vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/27198d2d-fdd5-4f74-8f54-7a9e5876e06d/small/vtv-therapeutics-color-jpg.jpg https://www.arubahealthmonitor.com/article/904364649-voting-rights-and-shares-capital-of-the-company Aruba Health Monitor en PressRelease 2026-04-07T20:15:00+00:00 Voting Rights and Shares Capital of the Company https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904364730-information-mensuelle-relative-au-nombre-total-de-droits-de-vote-et-d-actions-composant-le-capital-social Aruba Health Monitor en PressRelease 2026-04-07T20:15:00+00:00 Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904364771-avita-medical-showcases-acute-burn-and-wound-care-portfolio-at-aba-2026-featuring-new-cohealyx-data Aruba Health Monitor en PressRelease 2026-04-07T20:10:00+00:00 AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data https://ml.globenewswire.com/media/53ad8139-952a-4470-9ede-2f3bf0521f16/small/avita-png.png https://www.arubahealthmonitor.com/article/904364829-as-easter-travel-triggers-bed-bug-infestation-warning-fantastic-pest-control-rolls-out-faster-more-efficient-low-pesticide-heat-treatment Aruba Health Monitor en PressRelease 2026-04-07T20:06:00+00:00 As Easter Travel Triggers Bed Bug Infestation Warning Fantastic Pest Control Rolls Out Faster, More Efficient, Low-pesticide Heat Treatment https://pressranger.s3.us-west-1.amazonaws.com/3226340/65c749bddbdcebd94903357da3d456ca_44_file.jpg https://www.arubahealthmonitor.com/article/904364502-brightspring-health-services-inc-to-announce-first-quarter-2026-financial-results-on-may-1-2026 Aruba Health Monitor en PressRelease 2026-04-07T20:05:00+00:00 BrightSpring Health Services, Inc. to Announce First Quarter 2026 Financial Results on May 1, 2026 https://ml.globenewswire.com/media/db25f94c-83a2-46ba-8d53-c9a0768a71bd/small/brightspring-healthservices-jpg.jpg https://www.arubahealthmonitor.com/article/904364525-vaxcyte-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Aruba Health Monitor en PressRelease 2026-04-07T20:05:00+00:00 Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/7c0fe2be-057f-4a85-b783-cb22e2d6f94d/small/new-logo-with-tagline-jpg.jpg https://www.arubahealthmonitor.com/article/904364745-iridex-announces-new-partnership-with-eyeprogpo-to-expand-member-access-to-retina-laser-technology Aruba Health Monitor en PressRelease 2026-04-07T20:05:00+00:00 Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology https://ml.globenewswire.com/media/2bb80159-a920-428b-aa69-c2f32e3038c9/small/iridex-corporate-logo-horizontal-rgb-m02-jpg.jpg https://www.arubahealthmonitor.com/article/904364770-madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-listing-rule-5635-c-4 Aruba Health Monitor en PressRelease 2026-04-07T20:05:00+00:00 Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/8fec8de1-1a2e-4f6c-a679-fc43002276ba/small/madrigal-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904364836-amneal-to-report-first-quarter-2026-results-on-may-1-2026 Aruba Health Monitor en PressRelease 2026-04-07T20:01:00+00:00 Amneal to Report First Quarter 2026 Results on May 1, 2026 https://ml.globenewswire.com/media/a20d6f40-90af-422f-ab14-47208fdbad2f/small/amneal-rgb-k-png.png https://www.arubahealthmonitor.com/article/904355152-gelatin-trick-recipe-under-investigation-the-viral-doctor-approved-jello-weight-loss-hack-claims-evaluated-for-gelatide-drops Aruba Health Monitor en PressRelease 2026-04-07T19:14:40+00:00 Gelatin Trick Recipe Under Investigation: The Viral Doctor-Approved Jello Weight Loss Hack Claims Evaluated for Gelatide Drops https://zingfast.com/wp-content/uploads/2026/04/Gelatin-Trick-Recipe.jpg https://www.arubahealthmonitor.com/article/904354949-lemaitre-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Aruba Health Monitor en PressRelease 2026-04-07T18:39:10+00:00 LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/8b8755b7-6f04-4650-9c94-0a2d0654fd49/small/lemaitre-2color-rgb-jpg.jpg https://www.arubahealthmonitor.com/article/904345601-mhm-invests-237-5-million-to-create-a-healthier-future-across-south-texas Aruba Health Monitor en PressRelease 2026-04-07T17:47:05+00:00 MHM Invests $237.5 Million to Create a Healthier Future Across South Texas https://ml.globenewswire.com/media/MjM4YmQ3ZDgtN2QzYy00MjdjLTk2ODQtNDllZjc1MjY2N2FiLTEyOTc4OTgtMjAyNi0wNC0wNy1lbg==/tiny/Methodist-Healthcare-Ministrie.png https://www.arubahealthmonitor.com/article/904345599-global-dna-read-write-and-edit-market-to-surge-to-67-7-billion-by-2030-driven-by-crispr-advances-genomic-diagnostics-and-expanding-clinical Aruba Health Monitor en PressRelease 2026-04-07T17:44:41+00:00 Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.arubahealthmonitor.com/article/904345591-gluco-zen-drops-under-investigation-safety-concerns-arise-amid-researching-the-ingredients-side-effects-risk-for-glucozen Aruba Health Monitor en PressRelease 2026-04-07T17:35:22+00:00 Gluco Zen Drops Under Investigation: Safety Concerns Arise Amid Researching the Ingredients' Side Effects Risk for GlucoZen https://zingfast.com/wp-content/uploads/2026/04/Gluco-Zen-Drops.jpg https://www.arubahealthmonitor.com/article/904345226-genfit-announces-publication-of-the-2025-universal-registration-document Aruba Health Monitor en PressRelease 2026-04-07T17:30:00+00:00 GENFIT Announces Publication of the 2025 Universal Registration Document   https://ml-eu.globenewswire.com/media/YjA0MjRlZDQtMzQxZS00MDdhLTg3ZGEtZmVhOTQ4ZDQzZWI3LTEwMTEyNjgtMjAyNi0wNC0wNy1lbg==/tiny/GENFIT-S-A-.png https://www.arubahealthmonitor.com/article/904345280-genfit-mise-disposition-du-document-d-enregistrement-universel-2025 Aruba Health Monitor en PressRelease 2026-04-07T17:30:00+00:00 GENFIT : Mise à disposition du Document d’Enregistrement Universel 2025   https://ml-eu.globenewswire.com/media/YjA0MjRlZDQtMzQxZS00MDdhLTg3ZGEtZmVhOTQ4ZDQzZWI3LTEwMTEyNjgtMjAyNi0wNC0wNy1mcg==/tiny/GENFIT-S-A-.png https://www.arubahealthmonitor.com/article/904345559-natural-remedies-awarded-american-botanical-council-s-2026-varro-e-tyler-commercial-investment-in-phytomedicinal-research-award Aruba Health Monitor en PressRelease 2026-04-07T17:19:41+00:00 Natural Remedies Awarded American Botanical Council’s 2026 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award https://ml.globenewswire.com/media/afb640f0-73d1-4cd2-bcbe-9a80b381d7cc/medium/2026-abc-varro-e-tyler-commercial-investment-in-phytomedicin.jpg https://www.arubahealthmonitor.com/article/904336536-coeptis-announces-approval-of-z-squared-inc-s-nasdaq-listing-application Aruba Health Monitor en PressRelease 2026-04-07T16:05:56+00:00 Coeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing Application https://ml.globenewswire.com/media/6ef667b8-3767-4031-9180-f4ba33c81938/small/coeptis-logo-final-rgb-300dpi-png.png https://www.arubahealthmonitor.com/article/904327021-heartfocus-and-inteleos-launch-first-ai-cardiac-pocus-certification Aruba Health Monitor en PressRelease 2026-04-07T15:24:18+00:00 HeartFocus and Inteleos Launch First AI Cardiac POCUS Certification https://ml.globenewswire.com/media/NTFkODg1MzItY2Q4MC00MTY2LTk4NjItODc1OTc1OTA4YjUyLTEyNDUwMzItMjAyNi0wNC0wNy1lbg==/tiny/Inteleos-Inc-.png https://www.arubahealthmonitor.com/article/904326952-3-ways-pharmacists-can-help-maximize-your-glp-1-experience Aruba Health Monitor en PressRelease 2026-04-07T15:01:15+00:00 3 Ways Pharmacists Can Help Maximize Your GLP-1 Experience https://ml.globenewswire.com/Resource/Download/f72143cc-6829-468e-aeb9-94a8dbdcb874/17866-1.jpg https://www.arubahealthmonitor.com/article/904318679-speke-ai-to-showcase-ambient-ai-solutions-at-uca-s-2026-urgent-care-convention Aruba Health Monitor en PressRelease 2026-04-07T14:37:17+00:00 Speke AI to Showcase Ambient AI Solutions at UCA’s 2026 Urgent Care Convention https://ml.globenewswire.com/media/NTE3ZDRhZjgtMjgwNi00MGNkLThlOGItYmQwNzU4OTBiMDNkLTUwMDE1NDA4MS0yMDI2LTA0LTA3LWVu/tiny/Speke-AI.png https://www.arubahealthmonitor.com/article/904318654-nextel-medical-corp-announces-pivotal-milestone-in-commercial-launch-of-patent-protected-nanog-dna-cancer-screening-test Aruba Health Monitor en PressRelease 2026-04-07T14:30:00+00:00 NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test https://ml.globenewswire.com/media/ZmQ2OTkwNDMtN2QzOS00OWQ1LThhYzctYzg5MzFjMjgwODMwLTUwMDE1ODM1Mi0yMDI2LTA0LTA3LWVu/tiny/Exousia-Pro-Inc-.png https://www.arubahealthmonitor.com/article/904318466-bioora-and-octane-biotech-sign-letter-of-intent-to-expand-cell-therapy-manufacturing-using-the-cocoon-platform Aruba Health Monitor en PressRelease 2026-04-07T14:15:00+00:00 BioOra and Octane Biotech Sign Letter of Intent to Expand Cell Therapy Manufacturing Using the Cocoon® Platform https://ml.globenewswire.com/media/YzFhYmQ1NzYtNzA3My00Y2JiLWE2MGQtMjM3ZDBmYzMxNTJhLTEzMDQwMTAtMjAyNi0wNC0wNy1lbg==/tiny/Octane-Medical-Group.png https://www.arubahealthmonitor.com/article/904318295-regional-health-properties-reports-fourth-quarter-2025-results Aruba Health Monitor en PressRelease 2026-04-07T14:05:00+00:00 Regional Health Properties Reports Fourth Quarter 2025 Results https://ml.globenewswire.com/media/bfd51062-4a60-4cf0-9f2f-a4b109b52e4a/small/logo-jpg.jpg https://www.arubahealthmonitor.com/article/904318008-folia-health-launches-app-based-study-to-unlock-novel-real-world-evidence-of-symptom-burden-and-unmet-need-for-patients-and-caregivers-in-cidp Aruba Health Monitor en PressRelease 2026-04-07T14:00:00+00:00 Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP https://ml.globenewswire.com/media/858e11f4-96a0-4321-93eb-d278df849ccf/small/untitled-design-1-png.png https://www.arubahealthmonitor.com/article/904318126-inc-recognizes-u-s-oral-surgery-management-for-growth Aruba Health Monitor en PressRelease 2026-04-07T13:41:00+00:00 Inc. Recognizes U.S. Oral Surgery Management for Growth https://ml.globenewswire.com/media/9472c27c-8b6d-4c87-95fd-31f1f0140263/small/usosm-logo-png.png https://www.arubahealthmonitor.com/article/904310228-merakris-therapeutics-provides-fda-update-and-reports-interim-findings-for-mtx-001-in-venous-leg-ulcers Aruba Health Monitor en PressRelease 2026-04-07T13:30:00+00:00 Merakris Therapeutics Provides FDA Update and Reports Interim Findings for MTX-001 in Venous Leg Ulcers https://ml.globenewswire.com/media/5b9c5fed-3332-4d4d-b8b6-6ab1b15faaed/small/mrks-brand-logo-final-fullcolor-png.png https://www.arubahealthmonitor.com/article/904310391-nurexone-biologic-s-u-s-subsidiary-exo-top-and-florida-based-bioxtek-sign-strategic-loi-for-exosome-manufacturing-and-commercialization Aruba Health Monitor en PressRelease 2026-04-07T13:18:00+00:00 NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization https://ml.globenewswire.com/media/1514c671-cc84-4bcb-82d7-b834fce40882/small/nurexone-logo-rebrand-large-png.png https://www.arubahealthmonitor.com/article/904308717-cellution-biologics-inc-announces-official-entry-into-the-ocular-market-at-ascrs-with-the-launch-of-opticover Aruba Health Monitor en PressRelease 2026-04-07T13:11:00+00:00 Cellution Biologics Inc. Announces Official Entry into the Ocular Market at ASCRS with the Launch of OptiCover™ https://ml.globenewswire.com/media/10957e60-6696-483a-9df0-88f8713da811/medium/opticover.jpg https://www.arubahealthmonitor.com/article/904309254-srx-health-solutions-returns-5-69-in-march-2026-driven-by-emjx-artificial-intelligence-ai-engine Aruba Health Monitor en PressRelease 2026-04-07T13:05:00+00:00 SRx Health Solutions Returns +5.69% in March 2026 Driven by EMJX Artificial Intelligence (AI) Engine https://ml.globenewswire.com/media/768807fe-a29b-48f5-be44-977c8eaf49f0/small/srxlogo-jpg.jpg https://www.arubahealthmonitor.com/article/904310171-medx-holdings-reports-strong-q4-results-achieves-net-profitability-and-announces-strategic-partnerships-to-supercharge-franchise-expansion Aruba Health Monitor en PressRelease 2026-04-07T13:05:00+00:00 MEDX HOLDINGS REPORTS STRONG Q4 RESULTS, ACHIEVES NET PROFITABILITY, AND ANNOUNCES STRATEGIC PARTNERSHIPS TO SUPERCHARGE FRANCHISE EXPANSION https://ml.globenewswire.com/media/995733cb-620f-4ea6-b204-8b5b5689df30/small/medx-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904310583-treace-announces-first-surgical-cases-with-the-superbite-compression-screw-system Aruba Health Monitor en PressRelease 2026-04-07T13:04:29+00:00 Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System https://ml.globenewswire.com/media/6f3a2631-2457-4100-950a-3dec602ec68d/medium/superbite-compression-screw-system.png https://www.arubahealthmonitor.com/article/904308778-saladax-biomedical-to-expand-international-access-to-drug-level-testing-for-psychiatry-and-oncology Aruba Health Monitor en PressRelease 2026-04-07T13:00:00+00:00 Saladax Biomedical to Expand International Access to Drug Level Testing for Psychiatry and Oncology https://ml.globenewswire.com/media/M2NiMWYwYzAtNjA1My00OWFiLWFkN2ItZjY5YzgxNjE4MzI3LTUwMDEyNDYwOC0yMDI2LTA0LTA3LWVu/tiny/Saladax-Biomedical-Inc-.png https://www.arubahealthmonitor.com/article/904308956-pathai-and-medstar-health-announce-partnership-to-deploy-the-aisight-dx-digital-pathology-platform-and-advanced-ai-applications Aruba Health Monitor en PressRelease 2026-04-07T13:00:00+00:00 PathAI and MedStar Health Announce Partnership to Deploy the AISight® Dx Digital Pathology Platform and Advanced AI Applications https://ml.globenewswire.com/media/ab2bfc12-ae80-47c6-9345-a98783489ed7/small/pathai-logo-standard-png.png https://www.arubahealthmonitor.com/article/904309046-death-by-a-thousand-vendors-81-of-employers-are-hiring-just-to-keep-up-with-digital-health-vendor-sprawl Aruba Health Monitor en PressRelease 2026-04-07T13:00:00+00:00 Death by a Thousand Vendors: 81% of Employers Are Hiring Just to Keep Up with Digital Health Vendor Sprawl https://ml.globenewswire.com/media/b8d88974-2aeb-4baa-ad3b-2ab758ed4dd9/small/solera-main-logo-red-png.png https://www.arubahealthmonitor.com/article/904309197-lumin-health-appoints-matthew-mosquera-md-ms-as-regional-medical-director-and-site-director-of-lumin-cambridge Aruba Health Monitor en PressRelease 2026-04-07T13:00:00+00:00 Lumin Health Appoints Matthew Mosquera, MD, MS, as Regional Medical Director and Site Director of Lumin Cambridge https://ml.globenewswire.com/media/cb31fc23-dea3-476e-971b-6265973b0739/medium/matthew-mosquera.jpeg https://www.arubahealthmonitor.com/article/904310148-ai-and-online-health-information-are-booming-but-americans-don-t-fully-trust-what-they-find Aruba Health Monitor en PressRelease 2026-04-07T13:00:00+00:00 AI and Online Health Information Are Booming, But Americans Don’t Fully Trust What They Find https://ml.globenewswire.com/media/NjE3YzhiYjItN2E5Yy00MjE5LWI1YTQtMGUzMmVlZjY3NzM2LTUwMDE2MDA3Mi0yMDI2LTA0LTA3LWVu/tiny/American-Association-of-Nurse-.png https://www.arubahealthmonitor.com/article/904309350-outlook-therapeutics-announces-formal-dispute-resolution-request-for-ons-5010-lytenava-bevacizumab-vikg-accepted-by-fda Aruba Health Monitor en PressRelease 2026-04-07T12:50:00+00:00 Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA https://ml.globenewswire.com/media/cbff3302-f8d2-466a-beff-8c33252f9c70/small/otlk-png.png https://www.arubahealthmonitor.com/article/904309225-vivos-therapeutics-completes-private-placement-with-existing-private-equity-investor-new-seneca-partners Aruba Health Monitor en PressRelease 2026-04-07T12:45:00+00:00 Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners https://ml.globenewswire.com/media/22d07f60-2e17-421d-bbc3-748c2402061e/small/picture2-jpg.JPG https://www.arubahealthmonitor.com/article/904308798-moleculin-releases-next-ceo-corner-segment-highlighting-annamycin-s-non-cardiotoxic-profile Aruba Health Monitor en PressRelease 2026-04-07T12:36:00+00:00 Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile https://ml.globenewswire.com/media/7fa09722-2ef8-49fc-bc24-6b150093f8ba/small/mbrx-logo-png.png https://www.arubahealthmonitor.com/article/904299971-20-20-biolabs-selected-by-evexia-diagnostics-to-offer-onetest-for-cancer-through-evexia-platform Aruba Health Monitor en PressRelease 2026-04-07T12:31:00+00:00 20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform https://ml.globenewswire.com/media/bcaf95ca-9983-408c-bc61-646e4ee2f925/small/2020-biolabs-logo-png.png https://www.arubahealthmonitor.com/article/904299756-xenon-to-highlight-phase-3-x-tole2-long-term-data-for-azetukalner-in-focal-onset-seizures-at-2026-aan-annual-meeting Aruba Health Monitor en PressRelease 2026-04-07T12:30:00+00:00 Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting https://ml.globenewswire.com/media/505b89d3-dfd1-46e8-bc3b-3c9c699ef7ec/small/xenon-logo-tm-full-color-250x80px-png.png https://www.arubahealthmonitor.com/article/904299796-abeona-therapeutics-announces-appointment-of-keith-a-goldan-to-its-board-of-directors Aruba Health Monitor en PressRelease 2026-04-07T12:30:00+00:00 Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors https://ml.globenewswire.com/media/f11f9f14-9744-4666-aef3-9771488c41bd/small/thumb-1740-12-silhouette-vertical-full-color-png.png https://www.arubahealthmonitor.com/article/904299918-clover-health-empowers-members-to-take-charge-of-their-health-data-through-healthex-partnership Aruba Health Monitor en PressRelease 2026-04-07T12:30:00+00:00 Clover Health Empowers Members to Take Charge of Their Health Data Through HealthEx Partnership https://ml.globenewswire.com/media/1a48a25b-b654-4d62-adb3-d1a776346264/small/clover-logo-green-rgb-jpg.jpg https://www.arubahealthmonitor.com/article/904299951-integra-lifesciences-unveils-new-real-world-evidence-highlighting-primatrix-utilization Aruba Health Monitor en PressRelease 2026-04-07T12:30:00+00:00 Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® Utilization https://ml.globenewswire.com/media/00cf1e29-7492-4f89-bab1-6691cf2253c4/medium/primatrix-dermal-scaffold.png https://www.arubahealthmonitor.com/article/904299992-ss-innovations-to-host-smrsc-2026-in-new-delhi-india-from-april-9-11-2026 Aruba Health Monitor en PressRelease 2026-04-07T12:30:00+00:00 SS Innovations to Host SMRSC 2026 in New Delhi, India from April 9-11, 2026 https://ml.globenewswire.com/media/cef267e0-040f-4889-a706-cc4d0ae49e55/small/new-logo-april-23-2025-png.png https://www.arubahealthmonitor.com/article/904300074-cormedix-to-participate-in-needham-virtual-healthcare-conference Aruba Health Monitor en PressRelease 2026-04-07T12:30:00+00:00 CorMedix to Participate in Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/a14d732c-3f66-4a3c-96bb-7fc8ba5797bb/small/crmd-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904300165-milestone-pharmaceuticals-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Aruba Health Monitor en PressRelease 2026-04-07T12:30:00+00:00 Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/49b2e16b-2deb-4c9e-9c20-6cc4fd6c15ab/small/milestone-pharmaceuticals-logo-png.png https://www.arubahealthmonitor.com/article/904300233-cdt-notes-sarborg-publication-of-prism-framework-expanding-ai Aruba Health Monitor en PressRelease 2026-04-07T12:30:00+00:00 CDT Notes Sarborg Publication of PRISM Framework Expanding AI https://ml.globenewswire.com/media/MjNiMmZlYjctZjk3NS00MWViLThkMjktZWUwZGQ1YzVkNzRjLTEyNzQxMDItMjAyNi0wNC0wNy1lbg==/tiny/CDT-Equity-Inc-.png https://www.arubahealthmonitor.com/article/904299831-biorestorative-therapies-announces-strategic-collaboration-with-203-creates-to-build-and-commercialize-biocosmeceutical-platform Aruba Health Monitor en PressRelease 2026-04-07T12:15:00+00:00 BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform https://ml.globenewswire.com/media/a9a09a16-9f91-466d-a0b4-2a7f2fd05ebe/small/logo-png.png https://www.arubahealthmonitor.com/article/904299713-nextcure-receives-fast-track-designation-for-sim0505-cdh6-adc-in-ovarian-cancer Aruba Health Monitor en PressRelease 2026-04-07T12:05:00+00:00 NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer https://ml.globenewswire.com/media/df24cd65-0f3d-4ede-9e7a-c3f58ce6e9d4/small/logo-nextcure-jpg.jpg https://www.arubahealthmonitor.com/article/904300472-emergent-biosolutions-launches-new-narcan-nasal-spray-carrying-case-and-multipacks-alongside-college-campus-outreach-to-expand-opioid-overdose Aruba Health Monitor en PressRelease 2026-04-07T12:05:00+00:00 Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness https://ml.globenewswire.com/media/3fcbfc65-93d7-475f-9f23-b47fbf2ab8ca/medium/narcan-nasal-spray-multipacks.png https://www.arubahealthmonitor.com/article/904299511-evaxion-announces-last-patient-visit-in-one-year-extension-of-phase-2-trial-with-personalized-cancer-vaccine-evx-01 Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 https://ml-eu.globenewswire.com/media/19d0d69c-7f37-4d3b-8f26-2866d4ec3311/small/evaxion-deepblue-rgb-png.png https://www.arubahealthmonitor.com/article/904299601-lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/fa4a7bb1-f8ea-45e7-ba51-37077689a4fb/small/lyell-branding-color-rgb-102918a-copy-jpg.jpg https://www.arubahealthmonitor.com/article/904299705-inhibikase-therapeutics-announces-enrollment-of-first-patient-in-improve-pah-global-phase-3-study-of-ikt-001-in-the-treatment-of-pulmonary-arterial Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension https://ml.globenewswire.com/media/32b8d8bc-ebf8-43c0-866a-6613b22263b1/small/ikt-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904299752-amneal-announces-2-million-donation-to-support-patient-access-to-essential-medicines-during-parkinson-s-awareness-month Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month https://ml.globenewswire.com/media/a20d6f40-90af-422f-ab14-47208fdbad2f/small/amneal-rgb-k-png.png https://www.arubahealthmonitor.com/article/904299830-crispr-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/5dac7d0d-131d-4047-bab7-db8e0719bf58/small/crispr-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904299833-gatc-health-and-uc-irvine-announce-landmark-pnas-publication-validating-ai-platform-for-opioid-use-disorder-treatment Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 GATC Health and UC Irvine Announce Landmark PNAS Publication Validating AI-Platform for Opioid Use Disorder Treatment https://ml.globenewswire.com/media/8252f5cc-6aca-4b39-b708-845c0ce98b86/small/color-logo-vector-png.png https://www.arubahealthmonitor.com/article/904299835-solid-biosciences-to-participate-at-upcoming-investor-conferences Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Solid Biosciences to Participate at Upcoming Investor Conferences https://ml.globenewswire.com/media/bb5e6b30-d9d9-464f-8c64-33a09eacc3fb/small/solid-1029x579-png.png https://www.arubahealthmonitor.com/article/904299849-valitor-announces-oral-presentation-at-the-upcoming-association-for-research-in-vision-and-ophthalmology-arvo-2026-annual-meeting Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Valitor Announces Oral Presentation at the Upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting https://ml.globenewswire.com/media/58da3c80-c616-4358-9bbe-2936ace96649/small/valitor-sidebyside-png.png https://www.arubahealthmonitor.com/article/904299853-route-92-medical-announces-50-million-growth-financing Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Route 92 Medical Announces $50 Million Growth Financing https://ml.globenewswire.com/media/526036da-ddbe-4a9a-9222-9570f7cd6544/small/r-rt92-logo-rbg0-png.png https://www.arubahealthmonitor.com/article/904299871-akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium https://ml.globenewswire.com/media/c7f3708e-3328-4668-95c6-e7646efd653a/small/akebia-logo-fullcolor-rgb-png.png https://www.arubahealthmonitor.com/article/904299961-aclarion-highlights-growing-adoption-of-nociscan-at-the-london-clinic-with-new-physician-video Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://www.arubahealthmonitor.com/article/904300025-calidi-biotherapeutics-announces-speaker-presentation-at-asgct-conference-in-boston-on-may-14-2026-highlighting-the-redtail-platform-s-ability-to Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://www.arubahealthmonitor.com/article/904300073-corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-in-second-line-hnscc-and-cervical-cancer Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904300089-liquidia-corporation-to-participate-in-upcoming-investor-conferences Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Liquidia Corporation to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/f7659070-cc55-4e68-ae70-33013e7df72c/small/liquidia-new-logo-png.png https://www.arubahealthmonitor.com/article/904300151-electrocore-announces-first-patient-enrollment-in-investigator-led-study-of-gammacore-nvns-for-ptsd Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD https://ml.globenewswire.com/media/b80ed5b6-a449-461c-9034-85386286b09d/small/ec-logo-2018-tm-cmyk-jpg.jpg https://www.arubahealthmonitor.com/article/904300354-jupiter-neurosciences-appoints-kristopher-fishman-and-sanjiv-lal-to-nugevia-advisory-board Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board https://ml.globenewswire.com/media/4e829d7e-ecf6-46ad-98fe-479755d626e1/small/image-png.png https://www.arubahealthmonitor.com/article/904300403-polyrizon-ltd-announces-3-5-million-registered-direct-offering-and-private-placement Aruba Health Monitor en PressRelease 2026-04-07T12:00:00+00:00 Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement https://ml.globenewswire.com/media/N2M3NTE1MmItYWFmMi00MDNlLWE4MTItMWIxMDg4MWYwMTRlLTUwMDEyOTIyMy0yMDI2LTA0LTA3LWVu/tiny/Polyrizon-Ltd-.png https://www.arubahealthmonitor.com/article/904300175-artelo-biosciences-regains-compliance-with-nasdaq-listing-requirements Aruba Health Monitor en PressRelease 2026-04-07T11:50:00+00:00 Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements https://ml.globenewswire.com/media/460502d7-b0d3-43d8-a15a-5b2bb963bbbb/small/artelo-jpg.jpg https://www.arubahealthmonitor.com/article/904299627-marvel-biosciences-secures-financial-and-strategic-investment-with-5-horizon-ventures Aruba Health Monitor en PressRelease 2026-04-07T11:30:00+00:00 Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures https://ml.globenewswire.com/media/d49e32dc-88d9-4694-a3dd-6e663548e80d/small/picture1-png.png https://www.arubahealthmonitor.com/article/904299632-anavex-life-sciences-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Aruba Health Monitor en PressRelease 2026-04-07T11:30:00+00:00 Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/1b0f858f-4f7f-4f50-b691-a25307283fb5/small/anavexlogor-transparent-3x-png.png https://www.arubahealthmonitor.com/article/904299759-everbright-health-announces-ai-enabled-platform-to-unlock-access-to-advanced-mental-health-interventions Aruba Health Monitor en PressRelease 2026-04-07T11:30:00+00:00 Everbright Health Announces AI-Enabled Platform to Unlock Access to Advanced Mental Health Interventions https://ml.globenewswire.com/media/2ce4a623-23ed-4e51-9115-db1f2526bcfc/small/everbrighthealth-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904299841-plus-therapeutics-receives-ama-pla-code-for-cnside-csf-tumor-cell-enumeration-test-advancing-reimbursement-and-u-s-commercial-adoption Aruba Health Monitor en PressRelease 2026-04-07T11:30:00+00:00 Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption https://ml.globenewswire.com/media/92d7aa70-e37d-4870-bccf-d83b68ba5612/small/plus-logo-png.png https://www.arubahealthmonitor.com/article/904299993-cognition-therapeutics-to-present-at-needham-virtual-healthcare-conference Aruba Health Monitor en PressRelease 2026-04-07T11:30:00+00:00 Cognition Therapeutics to Present at Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/a14fd627-7ccb-45e2-95fe-792bbfb83231/small/2020-0227-cognition-logo-for-gnw-png.png https://www.arubahealthmonitor.com/article/904300070-palvella-therapeutics-appoints-accomplished-commercial-leader-kent-taylor-as-senior-vice-president-of-sales Aruba Health Monitor en PressRelease 2026-04-07T11:30:00+00:00 Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales https://ml.globenewswire.com/media/83fd569b-5e6c-46ad-882a-6430f8ab755a/small/palvella-2025-logo-new-jpg.jpg https://www.arubahealthmonitor.com/article/904300109-cervomed-to-provide-neflamapimod-clinical-program-update-and-participate-in-a-panel-on-biomarkers-at-2026-lewy-body-dementia-association-annual Aruba Health Monitor en PressRelease 2026-04-07T11:30:00+00:00 CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting https://ml.globenewswire.com/media/332fd58e-5e2b-4c96-8eaf-719ac2e34f52/small/cervomed-logo-png.png https://www.arubahealthmonitor.com/article/904300157-nervgen-pharma-announces-successful-end-of-phase-2-meeting-and-fda-alignment-on-restore-a-phase-3-registrational-study-of-nvg-291-for-chronic Aruba Health Monitor en PressRelease 2026-04-07T11:30:00+00:00 NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://www.arubahealthmonitor.com/article/904300328-weight-watchers-appoints-lisa-gavales-and-sue-gove-to-board-of-directors Aruba Health Monitor en PressRelease 2026-04-07T11:30:00+00:00 Weight Watchers Appoints Lisa Gavales and Sue Gove to Board of Directors https://ml.globenewswire.com/media/f435b439-7f75-4d2f-a6cc-0e4e2ed811ea/small/weightwatchers-wordmark-boldblue-png.png https://www.arubahealthmonitor.com/article/904290412-pluristyx-extends-patent-portfolio-in-universal-cell-therapy-with-new-u-s-patent-for-iact-stealth-technology Aruba Health Monitor en PressRelease 2026-04-07T11:09:00+00:00 Pluristyx Extends Patent Portfolio in Universal Cell Therapy with New U.S. Patent for iACT Stealth™ Technology https://ml.globenewswire.com/media/22e38345-b052-4cc3-a4c3-556e798109f3/small/pluristyx-logo-blue-apr22-png.png https://www.arubahealthmonitor.com/article/904290254-fennec-pharmaceuticals-announces-investigator-sponsored-study-to-be-conducted-by-university-of-arizona-cancer-center Aruba Health Monitor en PressRelease 2026-04-07T11:03:00+00:00 Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center https://ml.globenewswire.com/media/2eeb9b85-0beb-4bbe-a7af-1c0e9403db44/small/fennec-logo-png.png https://www.arubahealthmonitor.com/article/904290176-invivyd-launches-antibodies-for-any-body-in-partnership-with-world-champion-skier-lindsey-vonn-to-inspire-actions-that-help-support-immune-health Aruba Health Monitor en PressRelease 2026-04-07T11:01:00+00:00 Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png https://www.arubahealthmonitor.com/article/904290028-ac-immune-announces-amendment-to-morphomer-tau-license-and-collaboration-agreement-with-lilly Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg https://www.arubahealthmonitor.com/article/904290055-mediwound-to-present-new-escharex-data-at-leading-wound-care-conferences Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 MediWound to Present New EscharEx® Data at Leading Wound Care Conferences https://ml.globenewswire.com/media/55509183-b8b9-4da4-ae63-92c83760b5d9/small/mdwd-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904290057-radiopharm-theranostics-and-siemens-healthineers-sign-clinical-supply-agreement-for-rad101-in-the-u-s Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. https://ml-eu.globenewswire.com/media/8e246920-183e-46a4-b13c-a3c9ec50ada9/small/radx-logo-png.png https://www.arubahealthmonitor.com/article/904290245-sionna-therapeutics-to-participate-in-the-raymond-james-2026-biotech-innovation-symposium Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium https://ml.globenewswire.com/media/0cda8c25-e758-4f0d-86f2-875df8411a9a/small/sionna-png.png https://www.arubahealthmonitor.com/article/904290255-soleo-health-relocates-denver-specialty-pharmacy-to-support-continued-growth Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 Soleo Health Relocates Denver Specialty Pharmacy to Support Continued Growth https://ml.globenewswire.com/media/b3c4bcdc-fa25-4f50-8b81-09f13e80a008/small/soleo-logo-1024-x-1024-png.png https://www.arubahealthmonitor.com/article/904290282-breckenridge-distillery-introduces-honey-whiskey-crafted-with-rare-nigerian-goldswarm-honey-a-must-try-for-whiskey-enthusiasts Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 Breckenridge Distillery Introduces Honey Whiskey Crafted with Rare Nigerian Goldswarm Honey—A Must-Try for Whiskey Enthusiasts https://ml.globenewswire.com/media/cb623008-0c9a-49db-ab38-6e3062dd8bdb/medium/breckenridge-distillery-honey-whiskey.jpg https://www.arubahealthmonitor.com/article/904290354-climb-bio-announces-fda-fast-track-designation-for-budoprutug-for-the-treatment-of-primary-membranous-nephropathy Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy https://ml.globenewswire.com/media/2a42b557-6e44-4818-bfce-2238a05f2c43/small/climb-400x400-002-jpg.jpg https://www.arubahealthmonitor.com/article/904290361-skye-bioscience-presenting-at-glp-1-based-therapeutics-summit Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit https://ml.globenewswire.com/media/905e06d8-af43-4f7a-b097-8c12ce1d3aa0/small/skye-darkblue-jpg.jpg https://www.arubahealthmonitor.com/article/904290381-nurix-therapeutics-to-participate-in-upcoming-investor-conference Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 Nurix Therapeutics to Participate in Upcoming Investor Conference https://ml.globenewswire.com/media/65f50366-0a4e-4329-b0f5-f737c6145524/small/new-primary-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904290410-fortrea-unveils-fortrea-intelligent-technology-to-help-sponsors-and-sites-run-smarter-more-integrated-trials Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials https://ml.globenewswire.com/media/9fbbe00b-8782-464e-83e6-5843c563884a/small/fortrea-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904290597-neuronetics-comments-on-letter-from-pointillist-family-office Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 Neuronetics Comments on Letter from Pointillist Family Office https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://www.arubahealthmonitor.com/article/904290600-okyo-pharma-announces-scientific-advisory-board-meeting-and-urcosimod-data-presentation-during-ascrs-annual-meeting Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting https://ml.globenewswire.com/media/23e4046d-dcf9-4dd1-945e-461e98a27d15/small/full-logo-okyo-jpg.jpg https://www.arubahealthmonitor.com/article/904290602-vantage-hemp-co-engages-acos-and-gpos-to-advance-participation-in-cms-cbd-pilot-program Aruba Health Monitor en PressRelease 2026-04-07T11:00:00+00:00 Vantage Hemp Co. Engages ACOs and GPOs to Advance Participation in CMS CBD Pilot Program https://ml.globenewswire.com/media/d38e4562-945b-4df7-8869-623c43be10f1/medium/inside-vantages-manufacturing-facility.jpg https://www.arubahealthmonitor.com/article/904290206-ani-pharmaceuticals-announces-publication-of-new-day-clinical-trial-results-in-ophthalmology Aruba Health Monitor en PressRelease 2026-04-07T10:50:00+00:00 ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology https://ml.globenewswire.com/media/24d1d851-9075-4d6e-b22c-0c23a5ef0b36/small/ani-logo-png.png https://www.arubahealthmonitor.com/article/904290397-bluejay-diagnostics-inc-announces-completion-of-624-patient-enrollments-in-symon-ii-pivotal-clinical-trial Aruba Health Monitor en PressRelease 2026-04-07T10:30:00+00:00 Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial https://ml.globenewswire.com/media/d0d4a766-5115-448d-ba8a-d522100949f1/small/bjdx-jpg.jpg https://www.arubahealthmonitor.com/article/904280802-serina-therapeutics-to-present-at-the-5th-lnp-formulation-process-development-summit Aruba Health Monitor en PressRelease 2026-04-07T10:00:00+00:00 Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit https://ml.globenewswire.com/media/7f8e4304-8465-4d4d-a7e3-ebc4eae51f29/small/yellow-burts-blue-text-1-png.png https://www.arubahealthmonitor.com/article/904280810-ascellahealth-named-to-financial-times-americas-fastest-growing-companies-2026-list Aruba Health Monitor en PressRelease 2026-04-07T10:00:00+00:00 AscellaHealth Named to Financial Times Americas’ Fastest Growing Companies 2026 List https://ml.globenewswire.com/media/5278c55f-330c-41a1-8446-d8b1a07bbc55/small/ah-logo-colornotag-4x-png.png https://www.arubahealthmonitor.com/article/904280821-greenwich-lifesciences-provides-update-on-patent-claims-potentially-doubling-gp2-market-potential Aruba Health Monitor en PressRelease 2026-04-07T10:00:00+00:00 Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg https://www.arubahealthmonitor.com/article/904263002-oculis-to-participate-in-upcoming-investor-conferences Aruba Health Monitor en PressRelease 2026-04-07T08:00:00+00:00 Oculis to Participate in Upcoming Investor Conferences https://ml-eu.globenewswire.com/media/f6fa6e90-83a4-4baa-a3b6-5483017d26b9/small/oculis-logo-gradient-jpg-resized-jpg.jpg https://www.arubahealthmonitor.com/article/904253341-sononeu-exits-stealth-as-key-part-of-us-government-funded-research-program-worth-up-to-41-3m-to-advance-sonogenetics-into-clinic Aruba Health Monitor en PressRelease 2026-04-07T07:00:00+00:00 SonoNeu exits stealth as key part of US Government-funded research program worth up to $41.3m to advance sonogenetics into clinic https://ml-eu.globenewswire.com/media/28b90f6b-ca31-4be4-92ca-1d1e341f55f3/small/sononeu-small-logo-png.png https://www.arubahealthmonitor.com/article/904235360-press-release-sanofi-s-lunsekimig-met-primary-and-key-secondary-endpoints-in-phase-2-respiratory-studies-in-asthma-and-crswnp Aruba Health Monitor en PressRelease 2026-04-07T05:00:00+00:00 Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904235375-communiqu-de-presse-le-lunsekimig-de-sanofi-a-atteint-les-crit-res-d-valuation-principal-et-secondaires-cl-s-dans-les-tudes-respiratoires-de-phase Aruba Health Monitor en PressRelease 2026-04-07T05:00:00+00:00 Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.arubahealthmonitor.com/article/904203057-memogenesis-claims-evaluated-researching-the-latest-memo-genesis-formulation-facts Aruba Health Monitor en PressRelease 2026-04-07T01:10:16+00:00 MemoGenesis Claims Evaluated: Researching the Latest Memo Genesis Formulation Facts https://zingfast.com/wp-content/uploads/2026/04/MemoGenesis.jpg https://www.arubahealthmonitor.com/article/904203030-ryoncil-continues-successful-first-year-launch-with-net-sales-of-us-30-3m-in-march-quarter Aruba Health Monitor en PressRelease 2026-04-07T01:03:58+00:00 Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter https://ml.globenewswire.com/media/a9938a8a-a0ba-4708-abd5-2219515343fc/small/mesologo-png.png https://www.arubahealthmonitor.com/article/904187967-q1-2026-strong-revenue-growth-and-therapeutics-pipeline-advancement Aruba Health Monitor en PressRelease 2026-04-06T23:37:15+00:00 Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement https://ml.globenewswire.com/media/77ceffdf-31cc-415f-9747-efee950af329/small/telix-main-logo-3-png.png https://www.arubahealthmonitor.com/article/904187944-organogenesis-achieves-primary-endpoint-in-randomized-controlled-trial-of-puraply-am Aruba Health Monitor en PressRelease 2026-04-06T23:02:29+00:00 Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM https://ml.globenewswire.com/media/9c2f551f-b7b2-403a-bf43-78f1889401e5/small/organogenesis-jpg.jpg https://www.arubahealthmonitor.com/article/904174110-renovare-therapeutics-inc-announces-company-launch-and-collaboration-with-cu-boulder-awardee-of-up-to-33-5-million-in-arpa-h-funding-to-advance Aruba Health Monitor en PressRelease 2026-04-06T21:59:37+00:00 Renovare Therapeutics, Inc. Announces Company Launch and Collaboration with CU Boulder Awardee of up to $33.5 Million in ARPA-H Funding to Advance Osteoarthritis Regenerative Therapies https://ml.globenewswire.com/media/OTA0OGZiNjgtYTYzNi00MDUzLTk4YmYtYTMwMzBjYjVjMmNmLTEzMjIzODItMjAyNi0wNC0wNi1lbg==/tiny/Renovare-Therapeutics-Inc-.png https://www.arubahealthmonitor.com/article/904173827-avicanna-announces-changes-to-its-board-of-directors Aruba Health Monitor en PressRelease 2026-04-06T21:30:00+00:00 Avicanna Announces Changes to its Board of Directors https://ml.globenewswire.com/media/c9abc2f4-efdc-40f6-921d-a5da048eda46/small/avicanna-logo-colour-withtm-01-png.png https://www.arubahealthmonitor.com/article/904173889-organogenesis-announces-successful-fda-meeting-and-plan-to-file-bla-for-renu-for-knee-osteoarthritis-pain Aruba Health Monitor en PressRelease 2026-04-06T21:30:00+00:00 Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain https://ml.globenewswire.com/media/9c2f551f-b7b2-403a-bf43-78f1889401e5/small/organogenesis-jpg.jpg https://www.arubahealthmonitor.com/article/904167591-metabo-drops-claims-evaluated-recent-investigation-into-metabodrops-official-website-announcement Aruba Health Monitor en PressRelease 2026-04-06T21:16:34+00:00 Metabo Drops Claims Evaluated: Recent Investigation Into MetaboDrops Official Website Announcement https://zingfast.com/wp-content/uploads/2026/04/Metabo-Drops.jpg https://www.arubahealthmonitor.com/article/904161943-neuronetics-announces-chief-financial-officer-transition Aruba Health Monitor en PressRelease 2026-04-06T20:30:00+00:00 Neuronetics Announces Chief Financial Officer Transition https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://www.arubahealthmonitor.com/article/904162001-glyco-harmony-drops-claims-evaluated-explore-the-official-gluco-harmony-glycogen-support-website-facts Aruba Health Monitor en PressRelease 2026-04-06T20:21:12+00:00 Glyco Harmony Drops Claims Evaluated: Explore the Official Gluco Harmony Glycogen Support Website Facts https://zingfast.com/wp-content/uploads/2026/04/Glyco-Harmony-Drops.jpg https://www.arubahealthmonitor.com/article/904161867-silo-pharma-receives-european-patent-allowance-for-licensed-novel-ptsd-prevention-therapy Aruba Health Monitor en PressRelease 2026-04-06T20:15:00+00:00 Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy https://ml.globenewswire.com/media/3b635464-4382-4b8b-8175-39cc32e08050/small/logo-png.png https://www.arubahealthmonitor.com/article/904161146-outset-medical-names-derick-elliott-as-executive-vice-president-of-commercial Aruba Health Monitor en PressRelease 2026-04-06T20:05:00+00:00 Outset Medical Names Derick Elliott as Executive Vice President of Commercial https://ml.globenewswire.com/media/28778c78-03f1-4b17-9c13-3cc578c924dc/small/outset-id-orangegrey-png.png https://www.arubahealthmonitor.com/article/904161822-nanox-to-report-fourth-quarter-2025-financial-results-on-april-20-2026 Aruba Health Monitor en PressRelease 2026-04-06T20:05:00+00:00 Nanox to Report Fourth Quarter 2025 Financial Results on April 20, 2026 https://ml.globenewswire.com/media/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2/small/nano-logo-002-jpg.jpg https://www.arubahealthmonitor.com/article/904161913-immuneering-to-present-at-the-25th-annual-needham-virtual-healthcare-conference Aruba Health Monitor en PressRelease 2026-04-06T20:05:00+00:00 Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/81d0c83f-ae53-4d6e-9c5e-d6963e02f29d/small/immuneering-logo-cropped-1-jpg.jpg https://www.arubahealthmonitor.com/article/904161866-dianthus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Aruba Health Monitor en PressRelease 2026-04-06T20:01:00+00:00 Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/c9002285-2240-4dab-aced-77296f86a3fa/small/dianthus-logo-primary-full-color-cmyk-png.png https://www.arubahealthmonitor.com/article/904161983-ascendis-receives-orphan-drug-exclusivity-and-launches-yuviwel-navepegritide-in-the-united-states Aruba Health Monitor en PressRelease 2026-04-06T20:01:00+00:00 Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States https://ml.globenewswire.com/media/b4b7c29a-478e-4a8e-b23b-b6a1cb18aee8/small/ascendis-final-logo-7-23-15-png.png https://www.arubahealthmonitor.com/article/904161906-cytokinetics-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference Aruba Health Monitor en PressRelease 2026-04-06T20:00:00+00:00 Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference https://ml.globenewswire.com/media/52e2be9f-e9e3-43af-a747-123fdcac4253/small/cytokinetics-png.png https://www.arubahealthmonitor.com/article/904149403-mistr-founder-tristan-schukraft-joins-the-producing-team-of-titanique Aruba Health Monitor en PressRelease 2026-04-06T19:00:00+00:00 MISTR Founder Tristan Schukraft Joins the Producing Team of Titanique https://ml.globenewswire.com/media/NjA1ZGExYWItMDMwMC00NGI5LTk1ZTItM2NjNmIzZWNjZmNjLTUwMDEzNDg1Ny0yMDI2LTA0LTA2LWVu/tiny/MISTR.png https://www.arubahealthmonitor.com/article/904149512-glucozen-claim-evaluated-highly-effective-blood-sugar-support-for-natural-glucose-harmony Aruba Health Monitor en PressRelease 2026-04-06T18:40:44+00:00 GlucoZen Claim Evaluated: Highly-Effective Blood Sugar Support for Natural Glucose Harmony https://zingfast.com/wp-content/uploads/2026/04/GlucoZen-Drops.jpg https://www.arubahealthmonitor.com/article/904143857-global-validation-calibration-and-standardization-in-life-sciences-market-to-reach-3-9-billion-by-2030-fueled-by-regulatory-demands-and-digital Aruba Health Monitor en PressRelease 2026-04-06T18:00:00+00:00 Global Validation, Calibration and Standardization in Life Sciences Market to Reach $3.9 Billion by 2030, Fueled by Regulatory Demands and Digital Transformation https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.arubahealthmonitor.com/article/904143771-wellspan-health-announces-president-ceo-roxanna-gapstur-s-planned-retirement Aruba Health Monitor en PressRelease 2026-04-06T17:49:26+00:00 WellSpan Health announces President & CEO Roxanna Gapstur’s planned retirement https://ml.globenewswire.com/media/NGE2MDdiZGQtMzEyMy00NmIxLWE0ZTUtM2JmODBmOTQyOTg1LTEyMjE1MzQtMjAyNi0wNC0wNi1lbg==/tiny/WellSpan-Health.png https://www.arubahealthmonitor.com/article/904138873-dibs-ai-unveils-version-9-0-platform-suite-to-streamline-orthodontic-workflows Aruba Health Monitor en PressRelease 2026-04-06T17:30:00+00:00 DIBS AI Unveils Version 9.0 Platform Suite to Streamline Orthodontic Workflows https://ml.globenewswire.com/media/NzhmMTE3NzktZTQ1MS00OWY2LTkzMDgtZjAzYmU3OTY3YWI2LTEyMTI1MjAtMjAyNi0wNC0wNi1lbg==/tiny/OrthoSelect.png https://www.arubahealthmonitor.com/article/904129544-mistr-covers-florida-patients-as-adap-changes-create-gaps-in-hiv-treatment-access Aruba Health Monitor en PressRelease 2026-04-06T16:14:44+00:00 MISTR Covers Florida Patients as ADAP Changes Create Gaps in HIV Treatment Access https://ml.globenewswire.com/media/YTc5NzBiN2ItNDFmYy00MjgxLWJkOGYtMWVmZjk2ODRiM2JkLTUwMDEzNDg1Ny0yMDI2LTA0LTA2LWVu/tiny/MISTR.png https://www.arubahealthmonitor.com/article/904124434-biodesix-announces-aacr-2026-posters-and-presentations-highlighting-novel-diagnostic-test-discovery-pipeline-development Aruba Health Monitor en PressRelease 2026-04-06T15:43:00+00:00 Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development https://ml.globenewswire.com/media/b2fd8e3c-ff04-47d9-938d-93c9c961ccc3/small/bdsx-logo-1200x240-png.png https://www.arubahealthmonitor.com/article/904119613-yuzu-health-raises-35-million-series-a-to-modernize-health-insurance-plan-infrastructure Aruba Health Monitor en PressRelease 2026-04-06T15:00:00+00:00 Yuzu Health Raises $35 Million Series A to Modernize Health Insurance Plan Infrastructure https://ml.globenewswire.com/media/ZTNkMDYxNWQtZmVjYS00M2RlLWI0OWYtMzA2MGY0YjhlN2E2LTEzMjIzODUtMjAyNi0wNC0wNi1lbg==/tiny/Yuzu-Health.png https://www.arubahealthmonitor.com/article/904119642-hairclub-launches-100-000-aderans-helping-hearts-fund-to-support-employees-facing-life-s-unexpected-hardships Aruba Health Monitor en PressRelease 2026-04-06T15:00:00+00:00 HairClub Launches $100,000 Aderans Helping Hearts Fund to Support Employees Facing Life’s Unexpected Hardships https://ml.globenewswire.com/media/MDFmYjQwOTktMzE2MS00NTQ1LWI0ZDMtN2I4OWM2NDJjYzZjLTUwMDE1MzY4OS0yMDI2LTA0LTA2LWVu/tiny/HairClub.png https://www.arubahealthmonitor.com/article/904119717-celldex-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares Aruba Health Monitor en PressRelease 2026-04-06T14:53:52+00:00 Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/7a6cc287-087f-4e97-878f-7c1ed1dc5949/small/celldex-logo-rgb-png.png https://www.arubahealthmonitor.com/article/904115336-sienna-senior-living-recognized-by-the-globe-and-mail-s-women-lead-here-benchmark Aruba Health Monitor en PressRelease 2026-04-06T14:25:00+00:00 Sienna Senior Living recognized by The Globe and Mail’s Women Lead Here Benchmark https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://www.arubahealthmonitor.com/article/904111237-al-anon-family-groups-celebrates-75-years-of-recovery-providing-help-and-hope-to-families Aruba Health Monitor en PressRelease 2026-04-06T14:00:00+00:00 Al‑Anon Family Groups Celebrates 75 Years of Recovery — Providing Help and Hope to Families https://ml.globenewswire.com/media/293e2cf1-ce41-48e5-a66c-8a69496d5d01/small/al-anon-family-groups-logo.jpg https://www.arubahealthmonitor.com/article/904111343-adaptin-bio-shares-to-be-quoted-on-the-otcqb-under-ticker-symbol-aptn Aruba Health Monitor en PressRelease 2026-04-06T14:00:00+00:00 Adaptin Bio Shares to be Quoted on the OTCQB Under Ticker Symbol APTN https://ml.globenewswire.com/media/89fb59f4-0171-4319-995d-70be0b36378b/small/logo-png.png